Dynasil Corporation of America (DYSL) 10-Q 17 Feb 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Dec. 31, 2014	Feb. 06, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	DYNASIL CORP OF AMERICA
Entity Central Index Key	30831
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Trading Symbol	DYSL
Entity Common Stock, Shares Outstanding		16,401,983

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Sep. 30, 2014
Current Assets
Cash and cash equivalents	$2,504,000	$3,842,000
Accounts receivable, net of allowances of $304,000 and $299,000 at December 31, 2014 and September 30, 2014, respectively	3,338,000	3,240,000
Costs in excess of billings and unbilled receivables	1,291,000	1,235,000
Inventories, net of reserves	2,941,000	2,954,000
Prepaid expenses and other current assets	1,348,000	861,000
Total current assets	11,422,000	12,132,000
Property, Plant and Equipment, net	6,515,000	6,518,000
Other Assets
Intangibles, net	1,271,000	1,383,000
Goodwill	6,171,000	6,247,000
Deferred financing costs, net	36,000	39,000
Security deposits	58,000	58,000
Total other assets	7,536,000	7,727,000
Total Assets	25,473,000	26,377,000
Current Liabilities
Current portion of long-term debt	3,021,000	2,329,000
Capital lease obligations, current	152,000	134,000
Convertible notes	1,451,000	1,433,000
Accounts payable	1,251,000	1,602,000
Deferred revenue	29,000	103,000
Accrued expenses and other liabilities	2,398,000	2,503,000
Total current liabilities	8,302,000	8,104,000
Long-term Liabilities
Long-term debt, net of current portion	2,871,000	3,282,000
Capital lease obligations, net of current portion	80,000	95,000
Pension liability	0	318,000
Deferred tax liability	251,000	264,000
Other long-term liabilities	37,000	0
Total long-term liabilities	3,239,000	3,959,000
Stockholders' Equity
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 17,175,191 and 17,140,182 shares issued, 16,365,031 and and 16,330,022 shares outstanding at December 31, 2014 and September 30, 2014, respectively.	9,000	9,000
Additional paid in capital	19,246,000	19,195,000
Accumulated other comprehensive income	222,000	98,000
Accumulated deficit	-4,466,000	-3,933,000
Less 810,160 shares of treasury stock - at cost	-986,000	-986,000
Total Dynasil stockholders' equity	14,025,000	14,383,000
Noncontrolling interest	-93,000	-69,000
Total stockholders' equity	13,932,000	14,314,000
Total Liabilities and Stockholders' Equity	$25,473,000	$26,377,000

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Sep. 30, 2014
Allowance for doubtful accounts (in dollars)	$304,000	$299,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	17,175,191	17,140,182
Common stock, shares outstanding	16,365,031	16,330,022
Treasury stock, shares	810,160	810,160

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net revenue	$9,611,000	$10,712,000
Cost of revenue	6,018,000	6,261,000
Gross profit	3,593,000	4,451,000
Operating expenses:
Sales and marketing	365,000	397,000
Research and development	375,000	347,000
General and administrative	3,467,000	3,280,000
Gain on sale of assets	-185,000	-1,187,000
Total operating expenses	4,022,000	2,837,000
Income (loss) from operations	-429,000	1,614,000
Interest expense, net	125,000	213,000
Income (loss) before taxes	-554,000	1,401,000
Income tax (credit)	3,000	-44,000
Net income (loss)	-557,000	1,445,000
Less: Net loss attributable to noncontrolling interest	-24,000	-13,000
Net income (loss) attributable to common stockholders	-533,000	1,458,000
Net income (loss)	-557,000	1,445,000
Other comprehensive income (loss):
(Increase) decrease in pension liability	318,000	0
Foreign currency translation	-194,000	37,000
Total comprehensive income (loss)	($433,000)	$1,482,000
Basic net income (loss) per common share (in dollars per share)	($0.03)	$0.10
Diluted net income (loss) per common share (in dollars per share)	($0.03)	$0.10
Weighted average shares outstanding
Basic (in shares)	16,300,902	15,021,757
Diluted (in shares)	16,300,902	15,281,841

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2014	$14,314,000	$9,000	$19,195,000	$98,000	($3,933,000)	($986,000)	($69,000)
Balance (in shares) at Sep. 30, 2014		17,140,182				810,160
Stock-based compensation costs	65,000	0	65,000	0	0	0	0
Stock-based compensation costs (in shares)		41,820				0
Adjustment for escrow settlement	-17,000	0	-17,000	0	0	0	0
Adjustment for escrow settlement (in shares)		-9,642
Settlement of pension obligation, net of tax	318,000	0	0	318,000	0	0	0
Foreign currency translation adjustment	-194,000	0	0	-194,000	0	0	0
Net income (loss)	-557,000	0	0	0	-533,000	0	-24,000
Issuance of shares of common stock under employee stock purchase plan	3,000	0	3,000	0	0	0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)		2,831				0
Balance at Dec. 31, 2014	$13,932,000	$9,000	$19,246,000	$222,000	($4,466,000)	($986,000)	($93,000)
Balance (in shares) at Dec. 31, 2014		17,175,191				810,160

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	($557,000)	$1,445,000
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	65,000	120,000
Foreign exchange loss (gain)	-23,000	7,000
Gain on sale of assets	-185,000	-1,187,000
Depreciation and amortization	293,000	266,000
Pension expense	318,000	0
Other	-35,000	12,000
Other changes in assets and libilities:
Accounts receivable, net	-79,000	600,000
Inventories	12,000	-224,000
Costs in excess of billings and unbilled receivables	-56,000	-755,000
Prepaid expenses and other assets	-469,000	-219,000
Accounts payable	-360,000	-9,000
Accrued expenses and other liabilities	-438,000	274,000
Deferred revenue	-76,000	-167,000
Net cash from operating activities	-1,590,000	163,000
Cash flows from investing activities:
Proceeds from sale of assets	244,000	4,357,000
Purchases of property, plant and equipment	-244,000	-131,000
Net cash from investing activities	0	4,226,000
Cash flows from financing activities:
Proceeds from issuance of common stock	3,000	4,000
Payment of debt issuance costs	0	-1,000
Net proceeds from issuance of convertible notes	18,000	378,000
Principal payments on capital leases	-33,000	-30,000
Proceeds from short and long-term debt	300,000	0
Payments on long-term debt	-19,000	-4,389,000
Net cash from financing activities	269,000	-4,038,000
Effect of exchange rates on cash and cash equivalents	-17,000	-32,000
Net change in cash and cash equivalents	-1,338,000	319,000
Cash and cash equivalents, beginning	3,842,000	2,437,000
Cash and cash equivalents, ending	2,504,000	2,755,000
Non cash activities:
Assets purchased under capital leases	$73,000	$67,000

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 1 - Basis of Presentation
	The accompanying consolidated balance sheet as of December 31, 2014, the consolidated statements of operations and comprehensive income (loss) for the three months ended December 31, 2014 and 2013, changes in stockholders’ equity for the three months ended December 31, 2014 and cash flows for the three months ended December 31, 2014 and 2013 of Dynasil Corporation of America and subsidiaries (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.
	The preparation of our unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2014 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission.
	The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of December 31, 2014, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Acquisitions_and_Divestitures

Acquisitions and Divestitures	3 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Note 2 – Acquisitions and Divestitures
	On June 26, 2014, the Company and its wholly owned subsidiary, Evaporated Metal Films Corp. (“EMF”) acquired substantially all the assets of DichroTec Thin Films, LLC (“DichroTec”), a manufacturer of optical thin film coatings. The total purchase price paid of $1.7 million, consisting of approximately $0.5 million in cash and 690,000 shares of Dynasil common stock, was allocated primarily to machinery and equipment. DichroTec reported unaudited revenues of approximately $1.9 million for the twelve months ended December 31, 2013.
	On November 7, 2013, the Company sold its Lead Paint detector business to Protec Instrument Corporation (“Protec”), a wholly owned subsidiary of Laboratoires Protec S.A., a French corporation and former European distributor of the Company’s lead paint detector products. The sales price totaled approximately $1.2 million, including the assumption of certain liabilities of the Company by Protec. On December 23, 2013, the Company sold its Gamma Medical Probe business to Dilon Technologies, Inc., a Delaware corporation (“Dilon”), for $3.5 million, the assumption of certain liabilities of the Company, and a possible contingent payment. The Agreement also provided for $250,000 of the proceeds to be deposited in escrow for a year, which amount is included in accounts receivable in the Consolidated Balance Sheet. The Lead Paint Detector and Gamma Medical Probe businesses together comprised substantially all of the operating assets of the Company’s Instrument segment. The Company used $3.9 million of the proceeds from the two sale transactions to reduce its indebtedness to Santander Bank, N.A., its former lender.
	In connection with the sales of the two businesses, the Company recorded a gain of $1.2 million which is included in Income from Operations in the three months ended December 31, 2013. The businesses sold constituted substantially all of the Instruments segment but did not constitute a component of the business, and therefore did not qualify to be reported as discontinued operations.
	In the three months ended December 31, 2014, the Company recorded a gain of $0.2 million in connection with the sale of a product line in its Optics segment.

Xcede_Technologies_Inc_Joint_V

Xcede Technologies, Inc. Joint Venture	3 Months Ended
	Dec. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 3 – Xcede Technologies, Inc. Joint Venture
	In October, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology, which formerly comprised the majority of its biomedical segment. Xcede has raised approximately $1.4 million in external funding in the form of Convertible Notes from outside investors including certain officers and directors of the Company. The notes accrue interest at 5% and are due on demand after June 30, 2015. Upon the closing of a capital stock financing raising at least $3.0 million, inclusive of the convertible notes and interest, the outstanding principal amount of the notes plus all accrued interest will be converted into shares of the same capital stock sold in the financing at a 20% discount to the price per share of that capital stock. Alternatively, at any time prior to a capital stock financing the note holders can convert at their option the principal amount of the notes plus all accrued interest thereon into common stock based on a $5 million valuation.
	Xcede is 90% owned by Dynasil Biomedical and, as a result, is included in the Company’s consolidated balance sheet, results of operations and cash flows. The Company expects Xcede to require additional funding in connection with human trials expected to commence in the fourth quarter of 2015.

Inventories

Inventories	3 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories
	Inventories, net of reserves, consists of the following:
		December 31,		September 30,
		2014		2014
	Raw Materials	$	1,789,000	$	1,805,000
	Work-in-Process		839,000		858,000
	Finished Goods		313,000		291,000
		$	2,941,000	$	2,954,000

Intangible_Assets

Intangible Assets	3 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 5 – Intangible Assets
	Intangible assets at December 31, 2014 and September 30, 2014 consist of the following:
		Useful		Gross		Accumulated
	December 31, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	842,000	$	416,000	$	426,000
	Know How		15		512,000		222,000		290,000
	Trade Names		Indefinite		326,000		-		326,000
	Patents		20		124,000		-		124,000
	Biomedical Technologies		5		260,000		155,000		105,000
				$	2,064,000	$	793,000	$	1,271,000
		Useful		Gross		Accumulated
	September 30, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	877,000	$	409,000	$	468,000
	Know How		15		512,000		213,000		299,000
	Trade Names		Indefinite		339,000		-		339,000
	Patents		20		159,000		-		159,000
	Biomedical Technologies		5		260,000		142,000		118,000
				$	2,147,000	$	764,000	$	1,383,000
	Amortization expense for the three months ended December 31, 2014 and 2013 was $43,000 and $45,000, respectively. Estimated amortization expense for each of the next five fiscal years is as follows:
		2015 (9 months)		2016		2017		2018		2019		Thereafter		Total
	Acquired Customer Base	$	60,000	$	80,000	$	80,000	$	80,000	$	80,000	$	46,000	$	426,000
	Know How		26,000		34,000		34,000		34,000		34,000		128,000		290,000
	Patents		6,000		6,000		6,000		6,000		6,000		94,000		124,000
	Biomedical Technologies		45,000		60,000		-		-		-		-		105,000
		$	137,000	$	180,000	$	120,000	$	120,000	$	120,000	$	268,000	$	945,000

Goodwill

Goodwill	3 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	Note 6 – Goodwill
	Goodwill is subject to an annual impairment test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These include:
		·	A significant adverse long term outlook for any of its industries;
		·	An adverse finding or rejection from a regulatory body involved in new product regulatory approvals;
		·	Failure of an anticipated commercialization of a product or product line;
		·	Unanticipated competition or the introduction of a disruptive technology;
		·	The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
		·	A loss of key personnel; and
		·	An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of.
	There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three months ended December 31, 2014.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	3 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 7 – Earnings (Loss) Per Common Share
	Basic earnings (loss) per common share is computed by dividing the net income applicable or loss attributable to common shares by the weighted average number of common shares. Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods.
	For purposes of computing diluted earnings per share for the three months ended December 31, 2014 and 2013, no common stock options were included in the calculation of dilutive shares as all of the 21,980 and 630,532 common stock options outstanding, respectively, had exercise prices above the current quarterly average market price per share and their inclusion would be anti-dilutive. Additionally, for the three months ended December 31, 2014, no common share equivalents related to stock options or unvested restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would be anti-dilutive.
	The computation of the weighted shares outstanding for the three months ended December 31 is as follows:
		December 31, 2014		December 31, 2013
	Weighted average shares outstanding
	Basic		16,300,902		15,021,757
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		260,084
	Dilutive Average Shares Outstanding		16,300,902		15,281,841

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 - Stock Based Compensation
	The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model.
	A summary of stock option activity for the three months ended December 31, 2014 and 2013 is presented below:
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2014		430,532	$	3.33		0.31
	Outstanding and exercisable at September 30, 2014		430,532	$	3.33		0.31
	Granted		-		-
	Exercised		-		-
	Cancelled		-408,552	$	3.99
	Balance at December 31, 2014		21,980	$	3.03		2.09
	Outstanding and exercisable at December 31, 2014		21,980	$	3.03		2.09
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33		1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33		1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at December 31, 2013		630,532	$	3.33		0.81
	Outstanding and exercisable at December 31, 2013		630,532	$	3.33		0.81
	A summary of restricted stock activity for the three months ended December 31, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Three Months ended			Weighted-Average
	December 31, 2014	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2014		54,000	$	1.04
	Granted		-		-
	Vested		-		-
	Cancelled		-		-
	Nonvested at December 31, 2014		54,000	$	1.04
	Restricted Stock Activity for the Three Months ended			Weighted-Average
	December 31, 2013	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-		-
	Vested		-12,500		1.08
	Cancelled		-		-
	Nonvested at December 31, 2013		410,668	$	0.73
	Stock Compensation Expense for the three months ended December 31, 2014 and 2013 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	December 31, 2014		December 31, 2013
	Stock Grants	$	57,000	$	51,000
	Restricted Stock Grants		7,000		68,000
	Employee Stock Purchase Plan		1,000		1,000
	Total	$	65,000	$	120,000
	At December 31, 2014 there was approximately $48,000 in unrecognized stock compensation cost, which is expected to be recognized over a weighted average period of three months.

Segment_Customer_and_Geographi

Segment, Customer and Geographical Reporting	3 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 9 – Segment, Customer and Geographical Reporting
	Segment Financial Information
	Dynasil’s business is comprised of four segments: contract research (“Contract Research”), optics (“Optics”), instruments (“Instruments”) and biomedical (“Biomedical”). Substantially all the operating assets of the Instruments segment were sold in the three months ended December 31, 2013.
	Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Contract Research segment is one of the largest small business participants in U.S. government-funded research. The Optics segment manufactures optical materials, components and coatings. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture, is focused on developing a tissue sealant technology for a wide spectrum of applications though no assurance can be given that this technology will become successfully commercialized.
	The Company’s segment information for the three months ended December 31, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended December 31,
	2014
		Contract
		Research				Optics				Instruments				Biomedical		Total
	Revenue	$	4,663,000			$	4,948,000			$	-			$	-	$	9,611,000
	Gross Profit		2,098,000				1,495,000				-				-		3,593,000
	GM %		45	%			30.2	%			-				-		37.4	%
	SG&A		1,881,000				2,091,000				-				235,000		4,207,000
	Gain on sale of assets		-				185,000				-				-		185,000
	Operating Income (Loss)		216,000				-410,000				-				-235,000		-429,000
	Depreciation and Amortization		74,000				204,000				-				15,000		293,000
	Capital expenditures		-				244,000				-				-		244,000
	Intangibles, Net		290,000				752,000				-				229,000		1,271,000
	Goodwill		4,939,000				1,232,000				-				-		6,171,000
	Total Assets	$	9,036,000			$	15,226,000			$	289,000			$	922,000	$	25,473,000
	Results of Operations for the Three Months Ended December 31,
	2013
		Contract
		Research				Optics				Instruments				Biomedical		Total
	Revenue	$	5,840,000			$	4,099,000			$	773,000			$	-	$	10,712,000
	Gross Profit		2,530,000				1,597,000				324,000				-		4,451,000
	GM %		43.3	%			39	%			41.9	%			-		41.6	%
	SG&A		2,182,000				1,199,000				469,000				174,000		4,024,000
	Gain on sale of assets		-				-				1,187,000				-		1,187,000
	Operating Income (Loss)		348,000				398,000				1,042,000				-174,000		1,614,000
	Depreciation and Amortization		70,000				178,000				2,000				16,000		266,000
	Capital expenditures		-				131,000				-				-		131,000
	Intangibles, Net		324,000				870,000				-				163,000		1,357,000
	Goodwill		4,939,000				1,317,000				-				-		6,256,000
	Total Assets	$	10,360,000			$	12,538,000			$	752,000			$	505,000	$	24,155,000
	Customer Financial Information
	For the three months ended December 31, 2014, four customers of the Contract Research segment, all various agencies of the U.S. Government, each represented more than 10% of the total segment revenue. For the three months ended December 31, 2013, three customers, all various agencies of the U.S. Government, each represented more than 10% of the total segment revenue. For the three months ended December 31, 2014 and 2013, these customers made up 72% and 64%, respectively, of Contract Research revenue.
	For the three months ended December 31, 2014 and 2013, there was no customer in the Optics segment whose revenue represented more than 10% of the total segment revenue.
	For the three months ended December 31, 2014 and 2013, the Biomedical segment had no revenue.
	Geographic Financial Information
	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2014 and 2013 are as follows:
		Three Months Ended						Three Months Ended
		December 31, 2014						December 31, 2013
	Geographic Location	Revenue			% of Total			Revenue			% of Total
	United States	$	7,682,000			80	%	$	8,908,000			83	%
	Europe		884,000			9	%		830,000			8	%
	Other		1,045,000			11	%		974,000			9	%
		$	9,611,000			100	%	$	10,712,000			100	%

Income_Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income Taxes
	Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s U.K. subsidiary files tax returns in the U.K.
	The Company uses the asset and liability approach to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
	In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets.
	The Company applies the authoritative provisions related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority. As of December 31, 2014 and September 30, 2014, the Company has no unrecorded liabilities for uncertain tax positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations. As of December 31, 2014 and September 30, 2014, the Company had no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations in progress.
	The effective rate of (0.57%) for the three months ended December 31, 2014 and (3.12%) for the three months ended December 31, 2013 differs from the U.S. federal statutory income tax rate of 34% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset.
	The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2010 are still subject to examination.

Settlement_of_Pension_Liabilit

Settlement of Pension Liability	3 Months Ended
	Dec. 31, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule Of Defined Benefit Plans Disclosure [Text Block]	Note 11 – Settlement of Pension Liability
	On December 1, 2014, the Company terminated and settled its pension liability with each of the remaining participants in the EMF Defined Benefit Plan (the “Plan”). The Plan had been frozen since 2006. The total benefit payments made upon termination were $688,000 and the actual plan assets at the date of termination were $332,000. The Company funded and expensed the difference upon settlement of the Plan.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories, net of reserves, consists of the following:
		December 31,		September 30,
		2014		2014
	Raw Materials	$	1,789,000	$	1,805,000
	Work-in-Process		839,000		858,000
	Finished Goods		313,000		291,000
		$	2,941,000	$	2,954,000

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intangible assets at December 31, 2014 and September 30, 2014 consist of the following:
		Useful		Gross		Accumulated
	December 31, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	842,000	$	416,000	$	426,000
	Know How		15		512,000		222,000		290,000
	Trade Names		Indefinite		326,000		-		326,000
	Patents		20		124,000		-		124,000
	Biomedical Technologies		5		260,000		155,000		105,000
				$	2,064,000	$	793,000	$	1,271,000
		Useful		Gross		Accumulated
	September 30, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	877,000	$	409,000	$	468,000
	Know How		15		512,000		213,000		299,000
	Trade Names		Indefinite		339,000		-		339,000
	Patents		20		159,000		-		159,000
	Biomedical Technologies		5		260,000		142,000		118,000
				$	2,147,000	$	764,000	$	1,383,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense for each of the next five fiscal years is as follows:
		2015 (9 months)		2016		2017		2018		2019		Thereafter		Total
	Acquired Customer Base	$	60,000	$	80,000	$	80,000	$	80,000	$	80,000	$	46,000	$	426,000
	Know How		26,000		34,000		34,000		34,000		34,000		128,000		290,000
	Patents		6,000		6,000		6,000		6,000		6,000		94,000		124,000
	Biomedical Technologies		45,000		60,000		-		-		-		-		105,000
		$	137,000	$	180,000	$	120,000	$	120,000	$	120,000	$	268,000	$	945,000

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computation of the weighted shares outstanding for the three months ended December 31 is as follows:
		December 31, 2014		December 31, 2013
	Weighted average shares outstanding
	Basic		16,300,902		15,021,757
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		260,084
	Dilutive Average Shares Outstanding		16,300,902		15,281,841

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity for the three months ended December 31, 2014 and 2013 is presented below:
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2014		430,532	$	3.33		0.31
	Outstanding and exercisable at September 30, 2014		430,532	$	3.33		0.31
	Granted		-		-
	Exercised		-		-
	Cancelled		-408,552	$	3.99
	Balance at December 31, 2014		21,980	$	3.03		2.09
	Outstanding and exercisable at December 31, 2014		21,980	$	3.03		2.09
				Weighted Average		Weighted Average
		Options		Exercise Price per		Remain Contractual
		Outstanding		Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33		1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33		1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at December 31, 2013		630,532	$	3.33		0.81
	Outstanding and exercisable at December 31, 2013		630,532	$	3.33		0.81
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	A summary of restricted stock activity for the three months ended December 31, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Three Months ended			Weighted-Average
	December 31, 2014	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2014		54,000	$	1.04
	Granted		-		-
	Vested		-		-
	Cancelled		-		-
	Nonvested at December 31, 2014		54,000	$	1.04
	Restricted Stock Activity for the Three Months ended			Weighted-Average
	December 31, 2013	Shares		Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-		-
	Vested		-12,500		1.08
	Cancelled		-		-
	Nonvested at December 31, 2013		410,668	$	0.73
Schedule Of Stock Compensation Expense [Table Text Block]	Stock Compensation Expense for the three months ended December 31, 2014 and 2013 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	December 31, 2014		December 31, 2013
	Stock Grants	$	57,000	$	51,000
	Restricted Stock Grants		7,000		68,000
	Employee Stock Purchase Plan		1,000		1,000
	Total	$	65,000	$	120,000

Segment_Customer_and_Geographi1

Segment, Customer and Geographical Reporting (Tables)	3 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The Company’s segment information for the three months ended December 31, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended December 31,
	2014
		Contract
		Research				Optics				Instruments				Biomedical		Total
	Revenue	$	4,663,000			$	4,948,000			$	-			$	-	$	9,611,000
	Gross Profit		2,098,000				1,495,000				-				-		3,593,000
	GM %		45	%			30.2	%			-				-		37.4	%
	SG&A		1,881,000				2,091,000				-				235,000		4,207,000
	Gain on sale of assets		-				185,000				-				-		185,000
	Operating Income (Loss)		216,000				-410,000				-				-235,000		-429,000
	Depreciation and Amortization		74,000				204,000				-				15,000		293,000
	Capital expenditures		-				244,000				-				-		244,000
	Intangibles, Net		290,000				752,000				-				229,000		1,271,000
	Goodwill		4,939,000				1,232,000				-				-		6,171,000
	Total Assets	$	9,036,000			$	15,226,000			$	289,000			$	922,000	$	25,473,000
	Results of Operations for the Three Months Ended December 31,
	2013
		Contract
		Research				Optics				Instruments				Biomedical		Total
	Revenue	$	5,840,000			$	4,099,000			$	773,000			$	-	$	10,712,000
	Gross Profit		2,530,000				1,597,000				324,000				-		4,451,000
	GM %		43.3	%			39	%			41.9	%			-		41.6	%
	SG&A		2,182,000				1,199,000				469,000				174,000		4,024,000
	Gain on sale of assets		-				-				1,187,000				-		1,187,000
	Operating Income (Loss)		348,000				398,000				1,042,000				-174,000		1,614,000
	Depreciation and Amortization		70,000				178,000				2,000				16,000		266,000
	Capital expenditures		-				131,000				-				-		131,000
	Intangibles, Net		324,000				870,000				-				163,000		1,357,000
	Goodwill		4,939,000				1,317,000				-				-		6,256,000
	Total Assets	$	10,360,000			$	12,538,000			$	752,000			$	505,000	$	24,155,000
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2014 and 2013 are as follows:
		Three Months Ended						Three Months Ended
		December 31, 2014						December 31, 2013
	Geographic Location	Revenue			% of Total			Revenue			% of Total
	United States	$	7,682,000			80	%	$	8,908,000			83	%
	Europe		884,000			9	%		830,000			8	%
	Other		1,045,000			11	%		974,000			9	%
		$	9,611,000			100	%	$	10,712,000			100	%

Acquisitions_and_Divestitures_

Acquisitions and Divestitures (Details Textual) (USD $)	3 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 26, 2014	Dec. 31, 2013	Dec. 23, 2013	Nov. 07, 2013
Business Acquisition [Line Items]
Revenue, Net, Total	$9,611,000	$10,712,000
Gain (Loss) on Disposition of Business	200,000	1,200,000
Dichrotec [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross			500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			690,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			1,700,000
Revenue, Net, Total				1,900,000
Dilon [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets					3,500,000
Escrow Deposit					250,000
Proceeds from (Repayments of) Debt					3,900,000
Protec [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets						$1,200,000

Xcede_Technologies_Inc_Joint_V1

Xcede Technologies, Inc. Joint Venture (Details Textual) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2013	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Proceeds from Convertible Debt	$1.40
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Long-term Debt, Gross		3
Capital Stock Financing Discount Percentage		20.00%
Common Stock Valuation		$5
Equity Method Investment, Ownership Percentage		90.00%

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014
Inventory Current [Line Items]
Raw Materials	$1,789,000	$1,805,000
Work-in-Process	839,000	858,000
Finished Goods	313,000	291,000
Inventory, Net, Total	$2,941,000	$2,954,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross Amount	2,064,000	2,147,000
Accumulated Amortization	793,000	764,000
Net	1,271,000	1,383,000	1,357,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	842,000	877,000
Accumulated Amortization	416,000	409,000
Net	426,000	468,000
Acquired Customer Base [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Acquired Customer Base [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Gross Amount	512,000	512,000
Accumulated Amortization	222,000	213,000
Net	290,000	299,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	326,000	339,000
Accumulated Amortization	0	0
Net	326,000	339,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	20 years	20 years
Gross Amount	124,000	159,000
Accumulated Amortization	0	0
Net	124,000	159,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Gross Amount	260,000	260,000
Accumulated Amortization	155,000	142,000
Net	105,000	118,000

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
2015 (9 months)	$137,000
2016	180,000
2017	120,000
2018	120,000
2019	120,000
Thereafter	268,000
Total	945,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (9 months)	60,000
2016	80,000
2017	80,000
2018	80,000
2019	80,000
Thereafter	46,000
Total	426,000
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (9 months)	26,000
2016	34,000
2017	34,000
2018	34,000
2019	34,000
Thereafter	128,000
Total	290,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (9 months)	6,000
2016	6,000
2017	6,000
2018	6,000
2019	6,000
Thereafter	94,000
Total	124,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (9 months)	45,000
2016	60,000
2017	0
2018	0
2019	0
Thereafter	0
Total	$105,000

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$43,000	$45,000

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Weighted average shares outstanding
Basic	16,300,902	15,021,757
Effect of dilutive securities
Dilutive Average Shares Outstanding	16,300,902	15,281,841
Employee Stock Option [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0
Restricted Stock [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	260,084

Earnings_Loss_Per_Common_Share3

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Loss Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,980	630,532

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance,Options Outstanding	430,532		630,532
Outstanding and exercisable,Options Outstanding	430,532		630,532
Granted,Options Outstanding	0		0
Exercised,Options Outstanding	0		0
Cancelled, Options Outstanding	-408,552		0
Balance,Options Outstanding	21,980	430,532	630,532	630,532
Outstanding and exercisable,Options Outstanding	21,980	430,532	630,532	630,532
Balance,Weighted Average Exercise Price per Share	$3.33		$3.33
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33		$3.33
Granted,Weighted Average Exercise Price per Share	$0		$0
Exercised,Weighted Average Exercise Price per Share	$0		$0
Cancelled,Weighted Average Exercise Price per Share	$3.99		$0
Balance,Weighted Average Exercise Price per Share	$3.03	$3.33	$3.33	$3.33
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.03	$3.33	$3.33	$3.33
Balance,Weighted Average Remain Contractual Term (in Years)	2 years 1 month 2 days	3 months 22 days	9 months 22 days	1 year 22 days
Outstanding and exercisable,Weighted Average Remain Contractual Term (in Years)	2 years 1 month 2 days	3 months 22 days	9 months 22 days	1 year 22 days

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Nonvested, Beginning Balance	54,000	423,168
Shares, Granted	0	0
Shares, Vested	0	-12,500
Shares, Cancelled	0	0
Shares, Nonvested, Ending Balance	54,000	410,668
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance	$1.04	$0.74
Weighted-Average Grant-Date Fair Value, Granted	$0	$0
Weighted-Average Grant-Date Fair Value, Vested	$0	$1.08
Weighted-Average Grant-Date Fair Value, Cancelled	$0	$0
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance	$1.04	$0.73

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	$65,000	$120,000
Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	57,000	51,000
Resticted Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	7,000	68,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	$1,000	$1,000

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	3 Months Ended
	Dec. 31, 2014
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$48,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 months

Segment_Customer_and_Geographi2

Segment, Customer and Geographical Reporting (Details) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$9,611,000	$10,712,000
Gross Profit	3,593,000	4,451,000
GM %	37.40%	41.60%
SG&A	4,207,000	4,024,000
Gain on sale of assets	185,000	1,187,000
Operating Income (Loss)	-429,000	1,614,000
Depreciation and Amortization	293,000	266,000
Capital expenditures	244,000	131,000
Intangibles, Net	1,271,000	1,357,000	1,383,000
Goodwill	6,171,000	6,256,000	6,247,000
Total Assets	25,473,000	24,155,000	26,377,000
Contract Research [Member]
Segment Reporting Information [Line Items]
Revenue	4,663,000	5,840,000
Gross Profit	2,098,000	2,530,000
GM %	45.00%	43.30%
SG&A	1,881,000	2,182,000
Gain on sale of assets	0	0
Operating Income (Loss)	216,000	348,000
Depreciation and Amortization	74,000	70,000
Capital expenditures	0	0
Intangibles, Net	290,000	324,000
Goodwill	4,939,000	4,939,000
Total Assets	9,036,000	10,360,000
Optics [Member]
Segment Reporting Information [Line Items]
Revenue	4,948,000	4,099,000
Gross Profit	1,495,000	1,597,000
GM %	30.20%	39.00%
SG&A	2,091,000	1,199,000
Gain on sale of assets	185,000	0
Operating Income (Loss)	-410,000	398,000
Depreciation and Amortization	204,000	178,000
Capital expenditures	244,000	131,000
Intangibles, Net	752,000	870,000
Goodwill	1,232,000	1,317,000
Total Assets	15,226,000	12,538,000
Instruments [Member]
Segment Reporting Information [Line Items]
Revenue	0	773,000
Gross Profit	0	324,000
GM %	0.00%	41.90%
SG&A	0	469,000
Gain on sale of assets	0	1,187,000
Operating Income (Loss)	0	1,042,000
Depreciation and Amortization	0	2,000
Capital expenditures	0	0
Intangibles, Net	0	0
Goodwill	0	0
Total Assets	289,000	752,000
Biomedical [Member]
Segment Reporting Information [Line Items]
Revenue	0	0
Gross Profit	0	0
GM %	0.00%	0.00%
SG&A	235,000	174,000
Gain on sale of assets	0	0
Operating Income (Loss)	-235,000	-174,000
Depreciation and Amortization	15,000	16,000
Capital expenditures	0	0
Intangibles, Net	229,000	163,000
Goodwill	0	0
Total Assets	$922,000	$505,000

Segment_Customer_and_Geographi3

Segment, Customer and Geographical Reporting (Details 1) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$9,611,000	$10,712,000
% of Total	100.00%	100.00%
United State [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	7,682,000	8,908,000
% of Total	80.00%	83.00%
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	884,000	830,000
% of Total	9.00%	8.00%
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$1,045,000	$974,000
% of Total	11.00%	9.00%

Segment_Customer_and_Geographi4

Segment, Customer and Geographical Reporting (Details Textual)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	37.40%	41.60%
Contract Research [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	45.00%	43.30%
Minimum [Member] | Optics [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Four Customers [Member] | Minimum [Member] | US Government [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	72.00%	64.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, Percent	0.57%	3.12%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%

Settlement_of_Pension_Liabilit1

Settlement of Pension Liability (Details Textual) (USD $)	1 Months Ended
	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefits Paid	$688,000
Defined Benefit Plan, Settlements, Benefit Obligation	$332,000